May 11, 2015
Mitsubishi Tanabe Pharma Corporation (MTPC) saw its sales inch up in FY2014 as royalty revenues from its multiple sclerosis drug Gilenya (fingolimod) and antidiabetic Invokana (canagliflozin) climbed to counter decreased sales in Japan. In the year ended in March, the...read more